$125M Series A: Ambros Therapeutics to Begin Phase 3 Trials for Non-Opioid Pain Therapy

Ambros Therapeutics launches with $125M to advance neridronate, a non-opioid therapy for CRPS-1. See how this Phase 3-ready ...